netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.06.02  Expand sub section  Calcium-channel blockers
Amlodipine 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Amlodipine Tablet 5mg 
Amlodipine Tablet 10mg 

 
   
Diltiazem Hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Diltiazem Hydrochloride 60mg tablets - FIRST LINE. For administration three times a day. No requirement for brand name prescribing.

Modified- release formulations should be prescribed by brand name.

Drug discontinuations
Slozem® 120mg, 180mg, 240mg and 300mg capsules* –discontinued from December 2019 (stock should run out by end of Feb 2020).

 
   
Felodipine 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Felodipine Tablet 2.5mg M/R 
Felodipine Tablet 5mg M/R 
Felodipine Tablet 10mg M/R

 
   
Nifedipine 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of nifedipine, prescribers should specify the brand to be dispensed.

Modified-release formulations may not be suitable for dose titration in hepatic disease. As per BNF 

Drug discontinuations
Adalat 5mg immediate release capsules* –discontinued from February 2019.
Adalat 10mg immediate release capsules* – discontinued after March 2019
Adalat Retard 10mg modified release tablets – discontinued after November 2018
Adalat Retard 20mg modified release tablets – discontinued August 2018
Adalat LA 20mg*, 30mg and 60mg prolonged release – out of stock until 2021.

*Bayer is the main supplier of these products. 

See UKMI memo below on treatment alternatives.

 
Link  UKMI: Adalat (nifedipine) products discontinuations and shortages
   
Nimodipine (Nimotop)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Nimodipine 30mg tablets

Restriction: For subarachnoid haemorrhage

 
   
Verapamil Hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Standard release tablets
Modified release formulations.

Securon SR tablets are cost-effective brands.

 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary